Allergan, Inc. (NYSE:AGN)‘s stock had its “outperform” rating restated by equities researchers at Leerink Swann in a report released on Wednesday, MarketBeat.com reports. They presently have a $393.00 target price on the stock, up from their previous target price of $355.00. Leerink Swann’s target price would indicate a potential upside of 24.17% from the company’s […]
